Summary
Daunorubicin Liposomal has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Cystic Fibrosis would be drug repurposing rather than first-in-human development. This does not mean it is approved for Cystic Fibrosis. ClinicalTrials.gov lists 1 registered trial linking Daunorubicin Liposomal to Cystic Fibrosis: 1 is currently recruiting. The most advanced is PHASE1, PHASE2 (NCT06526923). It plans or enrolled 15 participants. Registered activity dates to 2024. No published literature item is linked to Daunorubicin Liposomal and Cystic Fibrosis in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Cystic Fibrosis ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Progressive lung function decline; no spontaneous remission; historically median survival 30 years; now >50 years with CFTR modulators for eligible genotypes.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 23.0 (trials 3.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 1 total: 1 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | HFE |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06526923 | A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) 2024 | recruiting | PHASE1, PHASE2 | 15 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target HFE. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Daunorubicin Liposomal approved for Cystic Fibrosis?
Daunorubicin Liposomal has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Cystic Fibrosis would be drug repurposing rather than first-in-human development. This does not mean it is approved for Cystic Fibrosis. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Daunorubicin Liposomal in clinical trials for Cystic Fibrosis?
ClinicalTrials.gov lists 1 registered trial linking Daunorubicin Liposomal to Cystic Fibrosis: 1 is currently recruiting. The most advanced is PHASE1, PHASE2 (NCT06526923). It plans or enrolled 15 participants. Registered activity dates to 2024.
What does the evidence show for Daunorubicin Liposomal in Cystic Fibrosis?
Trials of Daunorubicin Liposomal in Cystic Fibrosis are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target HFE. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.